Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Asia Pacific Prostate Cancer Conference /
Lecture: Current standard of care in advanced disease

1st - 2nd Mar 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.14
Views: 2744

Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan

Dr Wayne YH Chang from Taipei, Taiwan, talks about the ‘Current standard of care in advanced disease’, focusing on castrate resistant prostate cancer (CRPC). He addresses current treatment strategies in CRPC, and explores the range of evidence supporting chemotherapy (such as doxetaxel which remains first-line treatment based on clinical study results), as well as the evidence supporting novel secondary hormonal therapies (such as abiraterone acetate and enzalutamide) and bone targeted therapy (such as radium-223). He also reviews the evidence supporting newer therapies under investigation.

This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation